Persistent Asset Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Persistent Asset Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Sell	1,164 -14,741	-93%	-$3.23M	0.08%	166
2026 Q1	$3.01M	Buy	15,905 +14,014	+741%	+$2.45M	1.12%	19
2025 Q4	$321K	Sell	1,891 -3,385	-64%	-$519K	0.14%	177
2025 Q3	$695K	Sell	5,276 -18,752	-78%	-$2.25M	0.48%	68
2025 Q2	$2.55M	Buy	24,028 +4,004	+20%	+$435K	1.89%	13
2025 Q1	$2.49M	Buy	+20,024	New	+$2.61M	2.09%	9

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Persistent Asset Partners's JAZZ Position: Q2 2026 in Review

Persistent Asset Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 93% in Q2 2026, selling an estimated $3.23M and leaving 1,164 shares worth $280K. The position accounts for 0.08% of the portfolio, ranked #166.

Persistent Asset Partners first reported a position in JAZZ in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.01M in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Persistent Asset Partners held 1,164 shares of Jazz Pharmaceuticals worth $280K as of Q2 2026.
Persistent Asset Partners sold 14,741 Jazz Pharmaceuticals shares in Q2 2026, an estimated $3.23M.
Jazz Pharmaceuticals made up 0.08% of Persistent Asset Partners's portfolio in Q2 2026, its #166 holding.
Persistent Asset Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Persistent Asset Partners's Jazz Pharmaceuticals position peaked at $3.01M in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.